JPRN-UMIN000012752已完成2 期
A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimen - NECTOR
ational Cancer Center Hospital East0 个研究点目标入组 25 人开始时间: 2014年1月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) NET G1 or G2 by WHO 2010 criteria 2) Interstitial pneumonia or plumonary fibrosis 3) Metastasis to the central nervous system 4) Concomitant malignancy within 3 years 5) Active infection (exept for hepatitis B or C viral infection) 6) Active gastrointestinal ulcer 7) Severe or uncontrollable complications, such as cardiovascular impairment, infection, diabetes mellitus, and pulmonary disease 8) Severe mental disorder 9) Continuous administration of steroid or immunosuppressant 10) Prior treatment of mTOR inhibitor 11) Pregnant or lactating women and women of childbearing age who were not using effective contraception 12) Patients who was judged to be inappropriate for this study by each investigators
研究者
相似试验
进行中（未招募）
不适用
evaluation of the activity of Everolimus as maintenance therapy for metastatic neuroendocrine carcinoma with pulmonary or gastroenteropancreatic origin.The aim of this study is to evaluate the activity of a maintenance therapy with everolimus 10 mg daily in patients with stable disease, partial response or complete response after 6 cycles of induction chemotherapy with cisplatin or carboplatin plus etoposide administered according to clinical practice.EUCTR2014-003951-72-ITGruppo Oncologico Italiano Ricerca Cancro (GOIRC)
已完成
2 期
A phase 2 trial of EVERolimus alternating with SUNitinib as first line therapy for advanced renal cell carcinomaRenal Cell CarcinomaACTRN12609000643279The University of Sydney55
终止
2 期
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine TumorsGastrointestinal TumorsPancreatic TumorsGastrointestinal Neuroendocrine TumorsPancreatic Neuroendocrine TumorsNCT01648465Hellenic Cooperative Oncology Group25
已完成
2 期
Everolimus for Patients With Relapsed/Refractory Germ Cell CancerGerm Cell CancerTesticular CancerNCT01242631Hannover Medical School25
Unknown
1 期
Everolimus and Capecitabine in Patients With Advanced MalignancyAdvanced MalignanciesNCT01079702Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)35